"10.1371_journal.pone.0097803","plos one","2014-05-19T00:00:00Z","Vincent Meininger; Pierre-Fran√ßois Pradat; Andrea Corse; Safa Al-Sarraj; Benjamin Rix Brooks; James B Caress; Merit Cudkowicz; Stephen J Kolb; Dale Lange; P Nigel Leigh; Thomas Meyer; Stefano Milleri; Karen E Morrison; Richard W Orrell; Gary Peters; Jeffrey D Rothstein; Jeremy Shefner; Arseniy Lavrov; Nicola Williams; Phil Overend; Jeffrey Price; Stewart Bates; Jonathan Bullman; David Krull; Alienor Berges; Bams Abila; Guy Meno-Tetang; Jens Wurthner","D√©partement des Maladies du Syst√®me Nerveux, Assistance Publique ‚Ä H√¥pitaux de Paris, Centre de R√©f√©rence Maladies Rares SLA, Groupe Hospitalier Piti√©-Salp√™tri√®re, Universit√© Pierre-et-Marie-Curie, Paris, France; Neuromuscular Pathology Lab, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Clinical Neuropathology, Kings College Hospital/Kings College London, London, United Kingdom; Carolinas Neuromuscular/Amyotrophic Lateral Sclerosis-Muscular Dystrophy Association Center, Department of Neurology, Carolinas Medical Center and University of North Carolina School of Medicine-Charlotte Campus, Charlotte, North Carolina, United States of America; Wake Forest School of Medicine, M Reynolds Tower, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America; Department of Neurology, Weill Cornell School of Medicine, New York, New York, United States of America; Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, Falmer, Sussex, United Kingdom; Department of Neurology, Charit√© ‚Ä Universit√§tsmedizin Berlin, Berlin, Germany; Centro Ricerche Cliniche, University Hospital G.B. Rossi, Verona, Italy; School of Clinical and Experimental Medicine, University of Birmingham and Neurosciences Department, Queen Elizabeth Hospital, Birmingham, United Kingdom; Department of Clinical Neuroscience, Institute of Neurology, University College London, London, United Kingdom; GlaxoSmithKline Clinical Unit Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom; Brain Science Institute, Johns Hopkins University, Department of Neurology, Baltimore, Maryland, United States of America; Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, United States of America; Neurosciences Therapy Area Unit, Medicines Discovery and Development, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom; Clinical Statistics, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom; Clinical Pharmacology, Science and Study Operations, BioPharm and Infectious Diseases, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom; BioPharm Translational Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom; Clinical Pharmacology Modelling & Simulation (Neurosciences), GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom; Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, United Kingdom; Oncology Translational Medicine, Novartis Basel, Switzerland; Unit√© Mixte de Recherche-678, Institut National de la Sant√© et de la Recherche M√©dicale - Universit√© Pierre-et-Marie-Curie, Groupe Hospitalier Piti√©-Salp√™tri√®re, Paris, France; Department of Neurology, Royal Free London NHS Foundation Trust, London, United Kingdom","Conceived and designed the experiments: VM P-FP JP SB NW AC JW BRB JBC KEM BA GM-T MC JS PNL. Performed the experiments: VM P-FP AC GP BRB JBC DL TM SM KEM RWO JW BRB. Contributed reagents/materials/analysis tools: NW JB AB DK SA-S. Wrote the paper: P-FP AL JP PO SB JDR BRB JBC SJK PNL DK. Provided data analysis and interpretation: VM P-FP AL PO SB NW JW BRB SJK AB. Undertook data collection: VM P-FP AC GP BRB JBC DL TM SM KEM RWO. Undertook ongoing medical monitoring during the study: JW BRB. Responsible for recruitment of patients: P-FP BRB KEM. Undertook a literature search: BA. Undertook data cleaning: NW. Provided pharmacokinetic data analysis and interpretation: JB AB. Provided immunohistochemistry and laser scanning cytometry analysis: DK. Provided histological examination and histochemical and immunohistochemistry assessment of muscle biopsies: SA-S.","AL, NW, PO, JP, SB, JB, DK, AB, BA and GM-T are employees of and hold stock in GlaxoSmithKline. JW was a full-time employee of GlaxoSmithKline at the time of study and holds shares in the company. He is now an employee of Novartis. GP was a full-time employee of GlaxoSmithKline at the time of study and holds shares in the company. He is now an employee of Hammersmith Medicines Research. VM has previously received a consultancy fee from GlaxoSmithKline. AC has previously acted as a consultant to GlaxoSmithKline at a single-day advisory board meeting. PNL received travel expenses and consultancy fees for his work on the advisory board of this development. JDR has previously received funding from NIH, MDA, Robert Packard Center for ALS research and has acted as a consultant for Psyadon Pharmaceutical, Biogen Pharma and Cytokinetics. MC is on the GlaxoSmithKline scientific advisory board. P-FP, BRB, JBC, SJK, DL, TM, SM, SA-S and KEM have no conflicts of interest to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","05","Vincent Meininger","VM",28,TRUE,15,12,NA,11,TRUE,FALSE,TRUE,1,"2",FALSE
